Dr Owain Millington, Chief Executive Officer at ILC Therapeutics, explores some of the areas of unmet need in infectious disease, and where the search for pleiotropic, broad-spectrum antivirals could lead drug development. Introduction Whilst the Covid-19 pandemic caused a step change in global investment for infectious diseases, there remains significant unmet need for broad-spectrum antivirals […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!